No phaseStatus unknownAge-related condition
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Study on the Efficacy and Safety of Tadalafil in Early Alzheimer's Disease
- Sponsor
- Tongji Hospital of Tongji University
- Enrollment
- 60 planned
- Conditions
- Alzheimers disease
- Interventions
- Tadalafil 5mg/tablet, orally once daily with warm water at fixed time, for 24 weeks; Tadalafil 10mg/tablet, orally once daily with warm water at fixed time, for 24 weeks; Placebo; 5mg/tablet, 10mg/tablet; orally once daily with warm water at fixed time, for 24 weeks
- Ages
- adults, older adults
- Registry
- ChiCTR2600131266
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed September 7, 2026
Primary outcomes
- Change in ADAS-Cog13 score from baseline to week 28;
History
Last registry update
Started
Registered